Stéphanie Oliveira is a Postdoctoral Researcher at the ICVS. She holds a B.Sc. in Applied Biology (2010) and a M.Sc. in Molecular Genetics (2012) from the University of Minho, and a Ph.D. in Ageing and Chronic Diseases (2022) from an Inter-University Doctoral Program between the University of Minho, University of Coimbra, and the NOVA University of Lisbon. During her academic studies, she mainly focused on the role of serotonergic signaling as a new therapeutic approach for spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease (MJD), contributing to unveil new possible therapeutic targets for this pathology.
Currently, her main research interests are to discover new therapeutic strategies for SCA3 and other neurodegenerative disorders, and to understand the molecular mechanism underlying these diseases. For her work, Stéphanie makes use of mouse and C. elegans animal models to study specific pharmacotherapeutic approaches and to uncover their molecular mechanisms.
In 2023, she obtained a Post-doctoral Fellowship Award from the USA National Ataxia Foundation (NAF) aiming at studying whether treatment with a multimodal antidepressant can improve motor symptoms of SCA3 in animal models. Presently, she is co-supervising one master student, having successfully concluded the supervision of one undergraduate student.
Stéphanie Oliveira is a Postdoctoral Researcher at the ICVS. She holds a B.Sc. in Applied Biology (2010) and a M.Sc. in Molecular Genetics (2012) from the University of Minho, and a Ph.D. in Ageing and Chronic Diseases (2022) from an Inter-University Doctoral Program between the University of Minho, University of Coimbra, and the NOVA University of Lisbon. During her academic studies, she mainly focused on the role of serotonergic signaling as a new therapeutic approach for spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease (MJD), contributing to unveil new possible therapeutic targets for this pathology.
Currently, her main research interests are to discover new therapeutic strategies for SCA3 and other neurodegenerative disorders, and to understand the molecular mechanism underlying these diseases. For her work, Stéphanie makes use of mouse and C. elegans animal models to study specific pharmacotherapeutic approaches and to uncover their molecular mechanisms.
In 2023, she obtained a Post-doctoral Fellowship Award from the USA National Ataxia Foundation (NAF) aiming at studying whether treatment with a multimodal antidepressant can improve motor symptoms of SCA3 in animal models. Presently, she is co-supervising one master student, having successfully concluded the supervision of one undergraduate student.
Articles
Duarte-Silva, S.*, Da Silva, J. D.*, Monteiro-Fernandes, D.*, Costa, M. D., Neves-Carvalho, A., Raposo, M., Soares-Cunha, C., Correia, J. S., Nogueira-Goncalves, G., Fernandes, H. S., Oliveira, S., Ferreira-Fernandes, A. R., Rodrigues, F., Pereira-Sousa, J., Vilasboas-Campos, D., Guerreiro, S., Campos, J., Meireles-Costa, L., Rodrigues, C. M. P., Cabantous, S., Sousa, S. F., Lima, M., Teixeira-Castro, A., & Maciel, P. (2024). Glucocorticoid receptor-dependent therapeutic efficacy of tauroursodeoxycholic acid in preclinical models of spinocerebellar ataxia type 3. The Journal of Clinical Investigation, 134(5), e162246. https://doi.org/10.1172/JCI162246
Da Silva, J. D., Oliveira, S., Pereira-Sousa, J., Teixeira-Castro, A., Costa, M. D., & Maciel, P. (2020). Loss of egli-1, the Caenorhabditis elegans Orthologue of a Downstream Target of SMN, Leads to Abnormalities in Sensorimotor Integration. Molecular Neurobiology, 57(3), 1553–1569. https://doi.org/10.1007/s12035-019-01833-0
Esteves, S.*, Oliveira, S.*, Duarte-Silva, S., Cunha-Garcia, D., Teixeira-Castro, A., & Maciel, P. (2019). Preclinical Evidence Supporting Early Initiation of Citalopram Treatment in Machado-Joseph Disease. Molecular Neurobiology, 56(5), 3626–3637. https://doi.org/10.1007/s12035-018-1332-1
Teixeira-Castro, A.*, Jalles, A.*, Esteves, S.*, Kang, S., da Silva Santos, L., Silva-Fernandes, A., Neto, M. F., Brielmann, R. M., Bessa, C., Duarte-Silva, S., Miranda, A., Oliveira, S., Neves-Carvalho, A., Bessa, J., Summavielle, T., Silverman, R. B., Oliveira, P., Morimoto, R. I., & Maciel, P. (2015). Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease. Brain: a Journal of Neurology, 138(Pt 11), 3221–3237. https://doi.org/10.1093/brain/awv262
Departing from previous work in which we developped cellular and animal models of Machado-Joseph disease, a neurodegenerative disorder caused by expansion of a polyglutamine tract in the protein ataxin-3 (ATXN3)…
This project addresses an unmet medical need- the lack of effective treatment for any of the aging-associated neurodegenerative diseases. Due to the worldwide aging of the population, by 2050 it is expected that over 135 million people…
Phone: +351 253 604 967
Fax: +351 253 604 809
Email: icvs.sec@med.uminho.pt
Life and Health Sciences
Research Institute (ICVS)
School of Medicine,
University of Minho,
Campus de Gualtar
4710-057 Braga
Portugal
Copyright ©2022 ICVS. All Rights Reserved
Copyright ©2022 ICVS. All Rights Reserved
Life and Health Sciences
Research Institute (ICVS)
School of Medicine,
University of Minho,
Campus de Gualtar
4710-057 Braga
Portugal
Copyright ©2022 ICVS. All Rights Reserved
Life and Health Sciences
Research Institute (ICVS)
School of Medicine,
University of Minho,
Campus de Gualtar
4710-057 Braga
Portugal
